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In 1971, Folkman showed that tumour growth was dependent on
the formation of new blood vessels (Folkman, 1971), a process
known as angiogenesis. Angiogenesis in carcinomas often corre-
lates with the likelihood of the development of metastases and
the prognosis of patients (Folkman, 1995). A number of different
angiogenic and anti-angiogenic factors are known to be involved
in the events that lead to endothelial cell proliferation, migration
and invasion (Rak et al, 1996). These include TNF-α , bFGF,
VEGF and various interleukins such as IL-6 and IL-12. It has
recently been reported that the proteins prostate-specific antigen
(Fortier et al, 1999), angiostatin (O’Reilly et al, 1997) and endo-
statin (O’Reilly et al, 1997) function as endogenous inhibitors of
angiogenesis and can be produced in response to tumour prolifera-
tion. A corollary to the hypothesis that angiogenesis is central to
tumour growth is that anti-angiogenic agents may represent a new
strategy for controlling cancer growth. 
Following extensive preclinical studies of angiogenesis
inhibitors in animals, anti-angiogenic agents are now starting to be
used in clinical practice (Folkman, 1995). Thalidomide has anti-
angiogenic activity and can eradicate experimental tumours in
mice (Ching et al, 1995). Its devastating teratogenic effects are
probably in part due to the inhibition of blood vessel growth in the
developing fetal limb bud (D’Amato et al, 1994). Recent publica-
tions suggest that its molecular effects are mediated through (i)
oxidative DNA damage caused by the generation of hydroxyl-free
radicals (Sauer et al, 2000), (ii) metabolites binding to guanine-
cytosine rich growth factor promoter sites (Stephens and Filmore,
2000). (iii) the down-regulation of several cell-surface adhesion
receptors (Thiel et al, 2000) and, (iv) enhancing the degradation of
mRNA of peptide-signalling molecules such as TNF-α and FGF
(Ching et al, 1995; Tavares et al, 1997; La Maestra et al, 2000). 
Clinically, thalidomide has been used to treat such diverse
conditions as graft-versus-host disease (Vogelsang et al, 1992),
inflammatory bowel disease (Rhodes et al, 1997; Sands and
Podolsky, 1999), refractory myeloma (Singhal et al, 1999) and
AIDS-associated apthous ulcers (Jacobson et al, 1997), Kaposi’s
sarcoma (Mitsuyasu, 2000) and photodermatitis (Berger et al,
1995). The United States Food and Drug Administration approved
the use of thalidomide in July 1998 for erythema nodosum
leprosum, an inflammatory manifestation of leprosy (Sampaio
et al, 1993). It may also have a role in treating cancer cachexia
because high levels of TNF-α have previously been linked to
cachexia and tumour-related malaise (Yoneda et al, 1991; Haslett,
1998). 
A recent study (Eisen et al, 2000) at the Royal Marsden
Hospital has evaluated the use of low dose (100 mg daily)
thalidomide in 66 patients with melanoma, renal cell, ovarian or
breast cancer. In patients with renal cell cancer, 3 responses were
observed and a further 3 patients had stable disease for more than
3 months. There were no responses in melanoma, ovarian or
breast cancer patients. Analysis of potential growth factors/angio-
genic markers demonstrated a non-significant trend towards
higher levels of VEGF being associated with disease progression.
The occurrence of stable disease in patients with metastatic renal
cancer is consistent with unpublished data from other groups.
These results led to the phase II trial we now report which involves
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patients with advanced renal cancer, with the concomitant evaluation
of plasma angiogenic marker and growth factor concentrations. 
PATIENTS AND METHODS 
Patient identification and eligibility 
Patients with histologically confirmed renal cell carcinoma were
eligible for entry into this study. Eligibility criteria included the
presence of metastatic disease that was measurable in at least one
diameter greater than 1 cm by clinical examination or imaging.
Patients were not allowed prior chemotherapy or immunotherapy
within 4 weeks or major surgery within 3 weeks of entry into the
study. Marker lesions were not allowed to have received radio-
therapy at any time and patients with cerebral metastases were
excluded. Patients had to be of ECOG/Zubrod performance status
0–2, older than 18 years and have a life expectancy greater than
3 months. No more than 3 prior treatment regimens, excluding
adjuvant therapy were allowed. 
Patients required adequate bone marrow reserve with white
blood count greater than 3 × 109 l–1, platelets greater than 100 ×
109 l–1, and a haemoglobin more than 10 g dl–1. Patients were also
required to have a normal serum creatinine or a glomerular filtra-
tion rate greater than 60 ml min–1 as assessed by a 51Cr-EDTA
clearance, in addition to adequate hepatic function defined as liver
function tests less than twice the normal values, unless due to
metastatic disease. Any woman of child-bearing potential had to
have a negative pregnancy test prior to receiving thalidomide and
use adequate contraception during the study. Patients with pre-
existing peripheral neuropathy of WHO grade 2 or greater as
assessed by sensory nerve action potential (SNAP) testing were
not eligible (Fullerton and Kremer, 1961). 
The protocol was approved by the Royal Marsden and North
Middlesex Hospitals Ethics Committees and all patients gave
written informed consent. 
Treatment 
Patients received incremental doses of thalidomide up to a planned
target dose of 600 mg daily (300 mg bd) according to the
following schedule: 
100 mg bd for 1 week 
100 mg mane, 200 mg nocte for 1 week 
200 mg bd for 2 weeks 
200 mg mane, 300 mg nocte for 1 week 
300 mg bd thereafter. 
Thalidomide was supplied by Penn Pharmaceuticals Limited,
Gwent, United Kingdom and treatment continued until there was
evidence of disease progression, unacceptable toxicity, or the
patient wished to stop treatment for any reason. Patients self-
administered thalidomide more than 2 hours after food and a good
fluid intake was advised. 
Patients with unacceptable drowsiness or constipation had their
thalidomide dose reduced by increments of 200 mg daily. Patients
with SNAP tests that showed a reduction of ≥ 40% had their treat-
ment stopped for 2 weeks and their dose of thalidomide reduced to
300 mg daily. A further SNAP test was performed 4–6 weeks after
this dose modification and if the new test score was stable or
improved, the dose of 300 mg was maintained. However, if the
SNAP score decreased by ≥ 50% from baseline at any time, treat-
ment was stopped. 
Assessment of response and toxicity 
Baseline investigations included complete blood count, serum
biochemistry, liver function tests, SNAP test, electrocardiogram
and serum pregnancy test for women of child-bearing potential. A
clinical examination, complete blood count and biochemistry were
carried out every month while on treatment. The SNAP test was
repeated at 1, 3, 6, 9 and 12 months during therapy and at 6
monthly intervals thereafter. 
Patients underwent imaging or clinical measurement, as appro-
priate, to assess their disease status at the start of treatment and
at 1, 3, 6, 9 and 12 months while on treatment. Response was
measured according to standard International Union Against
Cancer criteria. Toxicity was assessed according to WHO criteria
at monthly intervals. Patients who received at least 4 weeks of
treatment were assessable for response and all patients were
assessable for toxicity. The response duration was defined as the
time elapsed between the start of treatment with thalidomide and
the date of disease progression or the last follow-up evaluation. 
Plasma samples were taken in heparinised tubes at the start of
treatment and stored at –70˚C. They were analysed using quantita-
tive sandwich enzyme immunoassay kits for IL-6, IL-12, TNF-α ,
bFGF and VEGF levels (Quantikine kits, R&D systems,
Abingdon, United Kingdom). 
Statistical analyses 
A Gehan 2 stage design with 95% power at a 10% standard error
was used. It was originally intended to recruit 9 patients and if
there were no objective responses or stabilisation of disease the
trial was to be terminated. There was a 5% probability that this
would occur with a response or disease stabilising rate of 30%.
Further recruitment of 16 patients was carried out in the second
stage to obtain an estimate of the response rate with a standard
error of 10%. 
The non-parametric Wilcoxon test was employed to assess the
significance of changes in plasma levels of angiogenic markers.
The pre-treatment value of the angiogenic marker was compared with
6-month value (or the 3- or 9-month value if the 6-month value was
unavailable). The one-month value was used as the pre-treatment
value in the single patient in whom an immediate pre-treatment value
was not obtained. 
RESULTS 
Patient characteristics 
Between July 1998 and June 2000, 25 eligible patients with
advanced renal cell cancer under the care of the Royal Marsden or
the North Middlesex Hospital were entered into the study (median
follow-up 20 months). The median age of the patients was 51
(range 34–76 years). Nearly all had undergone prior surgery and
many had undergone extensive prior systemic treatment. The
majority had a performance status of 1 and 7 patients had an
ECOG performance status of 2 (Table 1). Progressive disease was
identified in all patients within 16 weeks prior to study entry
although this was not an inclusion criterion. 
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In this group, 2 patients achieved a PR and 12 had SD (SD ≥ 12
months in 2 patients, 6–12 months in 5 patients and 3–6 months in
5 patients, Table 2). 3 patients were not assessable for response
due to early removal from the trial because of toxicity. The overall
response rate by intention to treat was 8% (2/25) and for assessable
patients the response rate was 9% (2/22). The median survival
after commencing thalidomide in patients with renal cell cancer
was 9 months and 4 patients currently remain on treatment. 
The 2 patients with partial responses, one with small volume
lung metastases, the other with retroperitoneal disease (nephrec-
tomy bed recurrence and para-aortic lymph nodes) have main-
tained their partial responses for more than 12 months and both
remain on a reduced dose of thalidomide (200 mg bd) due to
toxicity. 
We have updated results from our previous study using 100 mg
daily as the median follow-up is now 36 months, as compared with
a median follow-up of 20 months at publication (Eisen et al, 2000).
In patients with advanced renal cell cancer, SD has been main-
tained for ≥ 12 an ≥ 6 months in 2 patients previously reported as
having SD for 3–6 months. In both of these cases, treatment was
stopped because 2 consecutive SNAP tests demonstrated wors-
ening scores within the range of 40–50% (clinical grade II
neuropathy). The combined median survival from the start of
thalidomide therapy for all 40 assessable patients with renal cell
cancer from both studies is 9 months (range 1–22+ months). 
Toxicity 
The most common side effects observed were lethargy, constipa-
tion and neuropathy (Table 3). Constipation generally responded
well to standard measures although the lethargy observed was
constant and more difficult to manage. No haematological toxicity
was observed secondary to thalidomide. 
6 patients with renal cell cancer did not reach 600 mg due to
lethargy (grade II) at lower doses in 3 patients and death 
due to progressive disease in a further 3 patients who had an initial
performance status of 2. Dose reductions were required in a further 11
patients with renal cancer who did reach the target dose. The toxicities
leading to these reductions were as follows: 5 patients due to ≥ grade
II neuropathy alone, 4 patients due to ≥ grade II lethargy alone, 1
patient due to constipation alone (grade III) and 1 patient due to a
combination of constipation and lethargy (both grade II). One
patient died suddenly after achieving SD for more than 6 months.
The cause of death was established at post-mortem as being due to
pulmonary emboli. 6 patients were in full time employment at the
start of treatment and none had time off while on thalidomide. 
Angiogenic markers 
Tables 4A and 4B illustrate the plasma concentrations of angio-
genic markers, TNF-α and IL-6 in consecutive plasma samples
(Table 4A, patients with SD ≥ 3 months or a PR; Table 4B, patients
Thalidomide treatment of renal cell cancer 955
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Table 1 Baseline patient characteristics 
Renal cancer (n = 25) 
Male 25 
Female 0 
Age (range) 51 (34–76 years) 
ECOG performance status 
03  
1 15 
27  
Previous treatment 
None 1 
Surgery 24 
Chemotherapy 0 
Radiotherapy 8 
Immunotherapy 10 
Immuno-chemotherapy 12 
Endocrine treatment 5 
≥ 2 of above treatments 11 
(excluding surgery) 
Sites of metastasis 
Soft tissue/lymph node only 4 
Lung ± soft tissue only 8 
Viscera 1 
Liver 6 
Other (eg. spleen, adrenal, bone) 7 
Number of disease/organ sites affected 
14  
2 15 
≥ 36  
Table 2 Responses to treatment with thalidomide 
Tumour type Assessable patients PD PR SD ≥ 12 months SD 6–12 months SD 3–6 months Median follow-up 
Current study 
RCC 22 5 (23%) 2 (9%) 2 (9%)  5 (23%) 5 (23%) 20 months 
95% CI (8–45) (1–29) (1–29) (8–45) (8–45) 
Previous study 
RCC24 18 12 (67%) 3 (17%) 0 0 3 (17%) 20 months 
(41–87) (4–41) (4–41) 
RCC+ 18* 12 (67%) 3 (17%)  1 (6%) 1 (6%) 1 (6%) 36 months 
95% CI (41–87%) (4–41%) (4–41%) (4–41%) (4–41%) 
+Updated results of previous study (Eisen et al, 2000) *12 patients have died. 95% Confidence intervals are in given in brackets after percentages for each category. 
RCC = Renal Cell Cancer; PD = progressive disease; SD = stable disease; CI = Confidence interval. 
Table 3 Toxicity (World Health Organisation Grade) in all 25 patients with
advanced renal cancer, worst grade per patient 
Grade I Grade II Grade III Grade IV 
Lethargy 3 (12%) 8 (32%) 2 (8%) – 
Oedema 2 (8%) –– –  
Constipation – 10 (40%) 1 (4%)  – 
Rash 1 (5%) –– –  
Neuropathy – 4 (16%) 1 (4%)  –
BJOC 01-2025 953-958  1/10/01  11:49 am  Page 955with PD). Patients with PD were often unavailable for repeated
venepuncture and thus there were too few samples for meaningful
statistical analysis from patients with renal cell cancer because so
many of these patients progressed rapidly. The data illustrate the
marked heterogeneity in levels of angiogenic markers, TNF-α and
IL-6, in this small sample of 10 patients with renal cell cancer. 
The non-parametric Wilcoxon test was used to analyse the
results (Table 5). Levels of TNF-α demonstrated a statistically
significantly decrease (P = 0.05) during thalidomide therapy in
patients with SD ≥ 3 months or a PR. Plasma VEGF levels were
notable for showing a statistically significant decrease during
thalidomide therapy in all patients with renal cell cancer (P =
0.05). Plasma levels of IL-12 were undetectable (< 0.781 pg ml–1)
in all 10 patients. 
Furthermore, the mean pre-treatment TFN-α level was
3.85 pg ml–1 in 4 patients without clinical benefit from thalidomide
(PR or SD ≥ 6 months) and 11.9 pg ml–1 for 6 patients with clinical
benefit, in whom cytokine levels were measured (P = 0.06,
Mann–Whitney test). 
DISCUSSION 
Thalidomide is reported to have particular anti-neoplastic activity
in patients with renal cell carcinoma (Eisen et al, 2000), refractory
myeloma (Singhal et al, 1999) and Kaposi’s sarcoma (Mitsuyasu,
2000) although efficacy in other tumour types such as high-grade
gliomas (Fine et al, 2000), breast or ovarian cancers and
melanoma appears to be limited (Eisen et al, 2000). Results from
this phase II trial of high-dose oral thalidomide confirm our
previous experience, that this drug is active in previously treated
patients with advanced renal cancer (Table 2) (Eisen et al, 2000). 
In the 22 out of 25 patients with renal cell cancer who were
assessable for response, 2 PRs were seen and SD ≥ 12 months was
observed in 2 patients. The 2 patients who achieved PR remain in
956 J Stebbing et al
British Journal of Cancer (2001) 85(7), 953–958 © 2001 Cancer Research Campaign
Table 4A Plasma concentrations of angiogenic markers, IL-6 and TNF-α in consecutive patients with
renal cell carcinoma (SD ≥ 3 months or PR), before and during treatment with thalidomide. Values given
are the mean of two individual measurements (pg ml–1) 
Time (response) VEGF bFGF IL-6  TNF-α
Patient 2 1 month (SD) 196 32 130  23 
2 months (SD) 297 2.5 5.5 5.4 
3 months (SD) 127 8.5 7.9 9.6 
Patient 3 pre-treatment 486 63 2.7  >32 
1 month (SD) 93 2.4 22 3.3 
3 months (SD) 169 8.8 3.2 >32 
6 months (SD) 97 3.6 20 2.1 
Patient 4 pre-treatment 361 12 161  4.4 
3 months (PR) 334 16 71 >32 
6 months (PR) 275 20 124 3.6 
Patient 5* pre-treatment 171 3.4 1.8 5.7 
1 month (SD) 160 5.2 2.1 7.7 
3 months (SD) 140 15 2.6 6.2 
9 months (SD) 146 2.5 4.6 3.9 
Patient 6 pre-treatment 79 5.5 1.5  3.8 
1 month (SD) 80 8.4 1.4 4.3 
3 months (SD) 590 47 7.6 – 
6 months (SD) 72 5.5 1 4.1 
Patient 7 pre-treatment 197 61 5.3  2.8 
1 month (SD) 317 42 15 20 
Patient 9 pre-treatment 58 4.9 13  2.7 
1 month (SD) 161 22 5.9 3.8 
3 months (SD) 98 5 5.8 2.3 
*Stopped thalidomide after 7 months due to neurotoxicity. 
Table 4B Plasma concentrations of angiogenic markers, IL-6 and TNF-α in
consecutive patients with renal cell carcinoma (PD only), before and during
treatment with thalidomide. Values given are the mean of two individual
measurements (pg/ml–1) 
Time (Response) VEGF bFGF IL-6 TNF-α
Patient 1 pre-treatment 141 3 13  5.7 
2 months (SD) 435 9.6 1 3.7 
3 months (PD) 103 9.5 4.3 3.9 
Patient 8 pre-treatment 57 2.2 3.3  3.7 
1 month (PD) 88 11 3 6.4 
Patient 10 pre-treatment 234 28 217  3.3 
1 month (SD) 140 28 302 >32 
3 months (PD) 95 4.2 161 >32 
Table 5 Ranges of plasma concentrations of angiogenic markers, IL-6 and
TNF-α from patients with renal cell carcinoma, concentration ranges in
pg ml–1 and P values shown (Wilcoxon test) 
VEGF bFGF IL-6 TNF-α
PR/SD ≥ 3 months 
Pre-treatment 58–486 3.4–63 1.5–161 2.7– > 32 
During treatment 72–590 2.4–47 1–130 2.1– > 32 
P value 0.12 0.69 0.34 0.05 
All patients 
Pre-treatment 57–486 2.2–63 1.5–217 2.7– > 32 
During treatment 72–590 2.4–47 1–302 2.1– > 32 
P value 0.05 0.50 0.12 0.16 
BJOC 01-2025 953-958  1/10/01  11:49 am  Page 956remission after more than 12 months and remain on 200 mg bd
thalidomide which is well tolerated. A further 5 patients achieved
stabilisation of their disease which lasted for more than 6 months.
We consider disease stabilisation to be significant in this group as
all patients had documented disease progression prior to study
entry. By this criterion 9 patients (41%; 95% CI: 21–64) derived
clinical benefit from this therapy. 
The median survival of 9 months is the same as that observed in
the updated results from our previous study. The combined data
from our 2 studies in patients with advanced renal carcinoma (n =
40) demonstrates a median survival of 9 months from the start of
thalidomide treatment with 5 patients achieving a PR (23%) and a
further 9 patients (41%) having stabilisation of their disease for ≥ 6
months. These results are comparable to those obtained in larger
studies with single agent subcutaneously administered interferon-
α in previously untreated patients (median survival 8.5 months,
response rate 13%) (Medical Research Council Renal Cancer
Collaborators, 1999). 
A well-documented side-effect of thalidomide is peripheral
neuropathy (Fullerton and Kremer, 1961) and dose reductions due
to this were required in 5 patients. The most common side effects
that we observed were constipation, which responded well to laxa-
tives, neuropathy and lethargy. This last side effect was found to be
constant and therefore more troublesome than the others. It should
be noted that because of these side effects, 60% of our patients
with renal cell cancer could not reach the planned target dose or
required a dose reduction after a period of time on 600 mg daily.
Patients subsequently tolerated a dose of 200 mg bd well with no
significant (grade III or IV) toxicities. 
One possible therapeutic target for thalidomide in renal cell
carcinoma is TNF-α which is secreted by these tumours (Elsasser-
Beile et al, 1999). This cytokine enhances neo-angiogenesis,
augments the stimulation of renal cancer cells by IL-6 (Koo and
Beldegrum, 1992; Konig et al, 1999), and is implicated in many of
the non-specific systemic symptoms of advanced malignancy
(Sampaio et al, 1993; Berger et al, 1995). In our patients who
demonstrated a PR or SD ≥ 3 months, the associated decrease in
plasma TNF-α with treatment was statistically significant (P =
0.05). Furthermore, the mean pretreatment TNF-α plasma levels
were 11.4 and 3.64 pg ml–1 in those patients that did and did not
obtain clinical benefit from treatment with thalidomide, respec-
tively (P = 0.06). These data are consistent with an anti-angiogenic
action of thalidomide in this patient population but also suggest
that thalidomide may be of particular use in the management of
patients with renal cell cancer who secrete high levels of TNF-α . 
Caution needs to be exercised when interpreting these findings
because of the wide ranges in the plasma levels of angiogenic
markers, TNF-α and IL-6 that we encountered in this small
sample. Furthermore the results only just reached statistical signif-
icance and this could be explained by the high initial TNF-α
plasma levels found in patients 2 and 3. A more accurate method
of studying the biological effects of anti-angiogenic agents such as
thalidomide involves the examination of biopsy material pre- and
post-treatment to assess vascularity and the expression of angio-
genic markers by in situ hybridisation techniques. Plasma levels of
IL-6, IL-12, bFGF and VEGF did not significantly correlate with
response to treatment in our study, a result observed in our
previous trial which assayed clotted serum samples (Eisen et al,
2000). 
The highest documented response rates in renal cell carcinoma
are seen with a combination of interferon-α , 5-fluorouracil and
interleukin-2 (IFI) (Lopez-Hanninen et al, 1996; Atzpodien et al,
1997). The IFI regimen, like other IL-2 based therapies, is associ-
ated with the induction of high levels of TNF-α (Weidmann et al,
1992). 12 of our patients had received this combination prior to
study entry and a possible explanation for our results is that a
proportion of patients demonstrated the documented phenomenon
of a late response to biotherapy. This is unlikely as disease
progression was observed in several patients who had IFI and
objective disease stabilisation appeared to occur within 1 month of
commencing thalidomide. 
There are now increasing data suggesting synergy between anti-
angiogenic agents and other cytotoxic drugs (Teicher et al, 1992, 1994,
1996). Furthermore, thalidomide has documented immunomodulatory
effects and therefore it may prove valuable as part of a multi-modality
anti-cancer strategy, rather than as a single therapy (Raje and
Anderson, 1999; Fine et al, 2000). Future trials could also address
its use as a single agent in the adjuvant setting. Our currently
accuring studies in patients with advanced renal cell cancer use a
target dose of 400 mg daily, largely because of the lethargy associ-
ated with 600 mg. 
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